Medtronic’s SCD-HeFT
This article was originally published in The Gray Sheet
Executive Summary
Sudden Cardiac Death in Heart Failure Trial completes follow-up phase with minimum of 30 months and average of 40 months follow-up, the firm says. Results are slated for release in the first quarter of 2004. The 2,521-patient trial, begun in 1997, compares ICD-implanted patient arrhythmia and mortality rates with drug and placebo arms in moderate heart failure patients at high risk for sudden cardiac arrest (1"The Gray Sheet" Feb. 17, 2003, p. 6)...
You may also be interested in...
Non-Ischemic Heart Failure Patients May Benefit From ICD – St. Jude Study
St. Jude Medical's DEFINITE study could influence national Medicare coverage policy for prophylactic ICD implants, which the agency will review following completion of a separate trial (SCD-HeFT) in 2004
Class IV Heart Failure Patients Almost Included In MCAC Coverage Vote
Medtronic anticipates October completion of its Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), with results to be presented at the American College of Cardiology meeting in spring 2004
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.